Leukemia | Topics

 
How the Study of Leukemias Inspired a Decades-Long Career
November 14, 2021

“I’ve done a lot of work [not only with] clinical trials, but also understanding the disease, the prognostic factors, and the management of adverse effects.”

Racial and Ethnic Diversity in Acute Leukemia Clinical Trials Does Not Appear to Improve With Disparity and Demographic Reporting Requirements
September 07, 2021

After implementing disparity and demographic reporting in acute leukemia clinical trials, investigators did not report an increase in diverse trial participants.

Medical World News® Inside the Practice: CancerNetwork® and Jeffery Auletta, MD, Discuss Mismatched and Unrelated Donor Stem Cell Transplants in Patients With Acute Leukemias and Myelodysplastic Syndrome
July 23, 2021

CancerNetwork® spoke with Jeffery Auletta, MD, about how the National Marrow Donor Program/Be The Match is using research initiatives to expand eligibility for stem cell transplants in for patient with acute leukemias and myelodysplastic syndrome.

Ibrutinib Represents Possible New Treatment Option for Pretreated Hairy Cell Leukemia
July 23, 2021

Results of a phase 2 trial show that ibrutinib was capable of inducing responses in some patients with hairy cell leukemia who were previously treated with standard therapy options in a prior line.

FDA Grants Fast Track Designation to SNDX-5613 for the Treatment of Relapsed/Refractory Acute Leukemias
June 30, 2021

SNDX-5613 has received a fast track designation from the FDA for the treatment of relapsed/refractory acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia.

Avapritinib Earns FDA Approval For Advanced Systemic Mastocytosis, Including Mast Cell Leukemia
June 16, 2021

Avapritinib is now fully approved to treated advanced systemic mastocytosis, according to phase 1 and phase 2 clinical trial data.

Vemurafenib Plus Rituximab Produced Durable Responses in Relapsed or Refractory Hairy-Cell Leukemia
May 28, 2021

A phase 2 trial evaluated the combination of vemurafenib plus rituximab, which produced a complete response in 87% of the evaluable patients with hairy-cell leukemia.

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia
February 24, 2021

A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.

Dan Pollyea, MD, MS, on Venetoclax and IDH Mutations in Patients With AML
January 21, 2021

The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.

Dan Pollyea, MD, MS, on the Discovery and Incidence of IDH1 and IDH2 mutations in Patients With AML
January 14, 2021

IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.